Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29422733 | 1.00 | ALPL (0.43) | ALPLNOTUMPDK2PDK1PDK3 | |
| SCHEMBL25371993 | 0.85 | PDK2 (0.46) | ALPLNOTUMPDK2PDK1PDK3 | |
| SCHEMBL10322914 | 0.84 | KDM4E (0.46) | ALPLNOTUMPDK2PDK1PDK3 | |
| SCHEMBL25564365 | 0.84 | NOTUM (0.46) | ALPLNOTUMGAAMRGPRX4CA12 | |
| SCHEMBL20762798 | 0.83 | GAA (0.53) | GAACA12CA1CA2CA7 | |
| SCHEMBL10322996 | 0.82 | ALDH1A1 (0.52) | ALPLNOTUMPDK2PDK1PDK3 | |
| SCHEMBL14914823 | 0.82 | NOTUM (0.47) | ALPLNOTUMPDK2PDK1PDK3 | |
| SCHEMBL24901671 | 0.82 | NOTUM (0.49) | ALPLNOTUMPDK2GAAMRGPRX4 | |
| SCHEMBL29422734 | 0.82 | NOTUM (0.47) | ALPLNOTUMPDK2PDK1PDK3 | |
| SCHEMBL6686898 | 0.81 | CA12 (0.52) | GAACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2022-09-22 | — | — | US | disclosed |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | OPNA IMMUNO-ONCOLOGY SA (CH) | 2022-09-20 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113710668-A | Condensed azines for EP300 or CBP modulation and indications therefor | 普莱希科公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| WO-2020210366-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEONE MEDICINES I GMBH (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEONE MEDICINES I GMBH (CH) | 2020-06-11 | — | — | US | disclosed |
| CN-110997677-A | Btk inhibitors with improved dual selectivity | 百济神州有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034009-A1 | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2019-02-21 | — | — | WO | disclosed |
| EP-2773634-B1 | ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDINE-1-CARBONLYMETHYL}AMINE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2773634-A1 | ROD -LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2- [4- (BI PHENYL - 4 - YL) - 1H - IMIDAZO - 2 - YL]PYRROLIDINE - 1 - CARBONLYMETHYL} AMINE | Theravance, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013067267-A1 | ROD -LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2- [4- (BI PHENYL - 4 - YL) - 1H - IMIDAZO - 2 - YL] PYRROLIDINE - 1 - CARBONLYMETHYL} AMINE | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | ALPL 1065/4885NOTUM 1307/4885PDK2 3928/4885 |
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | ALPL 3028/4885NOTUM 2781/4885PDK2 2559/4885 |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | ALPL 3028/4885NOTUM 2781/4885PDK2 2559/4885 |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BTK, SYK, LYN | ALPL 3028/4885NOTUM 2781/4885PDK2 2559/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | ALPL 1065/4885NOTUM 1307/4885PDK2 3928/4885 |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | EP300, CREBBP, HDAC11 | ALPL 4065/4885NOTUM 2380/4885PDK2 2041/4885 |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | ALPL 4074/4885NOTUM 2418/4885PDK2 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.